GlassScriptPhysician profile
Troy A Holdeman
NPI 1164641932
$4,979.07
in general payments reported to CMS, 2019-2025
42 companies · $1,140 in 2025
The $1,140 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $554 · 2020: $450 · 2021: $631 · 2022: $329 · 2023: $969 · 2024: $906 · 2025: $1,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,976 · Education: $38.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,976.18 |
| Education | $38.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,161.20 | 2020-2025 | |
| Pfizer INC. | $674.15 | 2019-2025 | |
| Lilly USA, LLC | $482.81 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $438.62 | 2019-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $285.69 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Astellas Pharma US INC | $194.66 | 2019-2025 | Veozah |
| Novo Nordisk INC | $174.62 | 2019-2024 | Rybelsus, Ozempic |
| Sumitomo Pharma America, INC. | $164.10 | 2024-2025 | Gemtesa |
| Abbott Laboratories | $126.20 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $124.80 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $122.60 | 2024-2025 | Rexulti |
| Daiichi Sankyo INC. | $116.79 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.43 | 2022-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $113.89 | 2022-2025 | |
| Allergan, INC. | $77.15 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $71.05 | 2021-2024 | Yupelri |
| Eisai INC. | $67.06 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $56.26 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $46.61 | 2020-2024 | |
| Glaxosmithkline, LLC. | $44.99 | 2023-2025 | Shingrix, Boostrix, Arexvy |
| Currax Pharmaceuticals LLC | $40.06 | 2021-2023 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.49 | 2019-2021 | |
| Exact Sciences Corporation | $27.53 | 2023 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $24.52 | 2019 | |
| Pacira Therapeutics, INC. | $24.24 | 2019 | |
| Cranial Technologies, INC | $19.93 | 2025 | Doc Band |
| Esperion Therapeutics, INC. | $19.63 | 2020 | |
| Amarin Pharma, INC. | $18.56 | 2021 | |
| Kyowa Kirin, INC. | $17.10 | 2021 | |
| Sanofi Pasteur INC. | $16.85 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.54 | 2019 | |
| Paratek Pharmaceuticals, INC. | $14.60 | 2025 | Nuzyra |
| Shire North American Group INC | $14.27 | 2019 | |
| Ironwood Pharmaceuticals, INC | $13.60 | 2020 | |
| Phathom Pharmaceuticals, INC. | $12.39 | 2025 | Voquezna |
| Radius Health, INC. | $12.08 | 2019 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Holdeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.